Evidence map›Paper›PMID 38219218›Full record

ArticleCell cycle (Georgetown, Tex.)

Telomere dynamics in human pluripotent stem cells.

Buyun Ma, Paula Martínez, Raúl Sánchez-Vázquez, Maria A Blasco

Open access · greenAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Buyun MaTelomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Paula MartínezTelomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Raúl Sánchez-VázquezTelomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Maria A BlascoTelomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Spanish National Cancer Research Centre · ES

Funding

European Research Council
6 · The paper itself

Abstract

Pluripotent stem cells (PSCs) are a promising source of stem cells for regenerative therapies. Stem cell function depends on telomere maintenance mechanisms that provide them with the proliferative capacity and genome stability necessary to multiply and regenerate tissues. We show here that established human embryonic stem cells (hESCs) have stable telomere length that is dependent on telomerase but not on alternative mechanisms based on homologous recombination pathways. Here, we show that human-induced pluripotent stem cells (hiPSCs) reprogrammed from somatic cells show progressive telomere lengthening until reaching a length similar to ESCs. hiPSCs also acquire telomeric chromatin marks of ESCs including decreased abundance of tri-methylated histone H3K9 and H4K20 and HP1 heterochromatic marks, as well as of the shelterin component TRF2. These chromatin features are accompanied with increased abundance of telomere transcripts or TERRAs. We also found that telomeres of both hESCs and hiPSCs are well protected from DNA damage during telomere elongation and once full telomere length is achieved, and exhibit stable genomes. Collectively, this study highlights that hiPSCs acquire ESC features during reprogramming and reveals the telomere biology in human pluripotent stem cells (hPSCs).

Indexed as

Pluripotent Stem CellsTelomeraseChromatinHistonesHumansTelomereTelomere HomeostasisChromatinHistonesTelomerasehESCshiPSCsTelomeraseTelomeres

Identifiers

PMID38219218
PMCPMC10936660
OpenAlexW4390858730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.